166 related articles for article (PubMed ID: 11036836)
1. Fas and Fas ligand gene polymorphisms in primary Sjögren's syndrome.
Bolstad AI; Wargelius A; Nakken B; Haga HJ; Jonsson R
J Rheumatol; 2000 Oct; 27(10):2397-405. PubMed ID: 11036836
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of IL-1 beta gene in Japanese patients with Sjögren's syndrome and systemic lupus erythematosus.
Muraki Y; Tsutsumi A; Takahashi R; Suzuki E; Hayashi T; Chino Y; Goto D; Matsumoto I; Murata H; Noguchi E; Sumida T
J Rheumatol; 2004 Apr; 31(4):720-5. PubMed ID: 15088297
[TBL] [Abstract][Full Text] [Related]
3. Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjögren's syndrome.
Downie-Doyle S; Bayat N; Rischmueller M; Lester S
Arthritis Rheum; 2006 Aug; 54(8):2434-40. PubMed ID: 16869018
[TBL] [Abstract][Full Text] [Related]
4. Fas gene polymorphisms in systemic lupus erythematosus and serum levels of some apoptosis-related molecules.
Arasteh JM; Sarvestani EK; Aflaki E; Amirghofran Z
Immunol Invest; 2010; 39(1):27-38. PubMed ID: 20064083
[TBL] [Abstract][Full Text] [Related]
5. Study of Fas (CD95) and FasL (CD178) polymorphisms in liver transplant recipients.
Marín LA; Muro M; Moya-Quiles MR; Miras M; Minguela A; Bermejo J; Sanchez-Bueno F; Parrilla P; Alvarez-López MR
Tissue Antigens; 2006 Feb; 67(2):117-26. PubMed ID: 16441482
[TBL] [Abstract][Full Text] [Related]
6. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjögren's syndrome.
Bolstad AI; Eiken HG; Rosenlund B; Alarcón-Riquelme ME; Jonsson R
Arthritis Rheum; 2003 Jan; 48(1):174-85. PubMed ID: 12528117
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants of chemokine receptor CCR7 in patients with systemic lupus erythematosus, Sjogren's syndrome and systemic sclerosis.
Kahlmann D; Davalos-Misslitz AC; Ohl L; Stanke F; Witte T; Förster R
BMC Genet; 2007 Jun; 8():33. PubMed ID: 17587445
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma.
Zhou RM; Wang N; Chen ZF; Duan YN; Sun DL; Li Y
J Gastroenterol Hepatol; 2010 Mar; 25(3):555-61. PubMed ID: 20074157
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of Fas-ligand mRNA in Sjögren's syndrome patients with enlarged exocrine glands.
Tsuzaka K; Matsumoto Y; Sasaki Y; Abe T; Tsubota K; Takeuchi T
Autoimmunity; 2007 Nov; 40(7):497-502. PubMed ID: 17966039
[TBL] [Abstract][Full Text] [Related]
10. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus.
Kanemitsu S; Ihara K; Saifddin A; Otsuka T; Takeuchi T; Nagayama J; Kuwano M; Hara T
J Rheumatol; 2002 Jun; 29(6):1183-8. PubMed ID: 12064832
[TBL] [Abstract][Full Text] [Related]
11. Genetic association between interleukin-10 promoter region polymorphisms and primary Sjögren's syndrome.
Hulkkonen J; Pertovaara M; Antonen J; Lahdenpohja N; Pasternack A; Hurme M
Arthritis Rheum; 2001 Jan; 44(1):176-9. PubMed ID: 11212157
[TBL] [Abstract][Full Text] [Related]
12. Association of transforming growth factor beta1 and tumor necrosis factor alpha polymorphisms with anti-SSB/La antibody secretion in patients with primary Sjögren's syndrome.
Gottenberg JE; Busson M; Loiseau P; Dourche M; Cohen-Solal J; Lepage V; Charron D; Miceli C; Sibilia J; Mariette X
Arthritis Rheum; 2004 Feb; 50(2):570-80. PubMed ID: 14872501
[TBL] [Abstract][Full Text] [Related]
13. Fas polymorphisms influence susceptibility to autoimmune hepatitis.
Hiraide A; Imazeki F; Yokosuka O; Kanda T; Kojima H; Fukai K; Suzuki Y; Hata A; Saisho H
Am J Gastroenterol; 2005 Jun; 100(6):1322-9. PubMed ID: 15929764
[TBL] [Abstract][Full Text] [Related]
14. Lack of Fas and Fas-L mutations in patients with lymphoproliferative disorders associated with Sjögren's syndrome and type II mixed cryoglobulinemia.
Bertolo F; De Vita S; Dolcetti R; Carbone A; Ferraccioli GF; Bartoli E; Boiocchi M
Clin Exp Rheumatol; 1999; 17(3):339-42. PubMed ID: 10410268
[TBL] [Abstract][Full Text] [Related]
15. Influence of STAT4 polymorphism in primary Sjögren's syndrome.
Palomino-Morales RJ; Diaz-Gallo LM; Witte T; Anaya JM; Martín J
J Rheumatol; 2010 May; 37(5):1016-9. PubMed ID: 20360187
[TBL] [Abstract][Full Text] [Related]
16. The role of interleukin-10 promoter polymorphisms in primary Sjogren's syndrome.
Willeke P; Gaubitz M; Schotte H; Becker H; Domschke W; Schlüter B
Scand J Rheumatol; 2008; 37(4):293-9. PubMed ID: 18612930
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population.
Wang LH; Ting SC; Chen CH; Tsai CC; Lung O; Liu TC; Lee CW; Wang YY; Tsai CL; Lin YC
J Oral Pathol Med; 2010 Feb; 39(2):155-61. PubMed ID: 20359312
[TBL] [Abstract][Full Text] [Related]
18. Induction of salivary gland epithelial cell injury in Sjogren's syndrome: in vitro assessment of T cell-derived cytokines and Fas protein expression.
Abu-Helu RF; Dimitriou ID; Kapsogeorgou EK; Moutsopoulos HM; Manoussakis MN
J Autoimmun; 2001 Sep; 17(2):141-53. PubMed ID: 11591123
[TBL] [Abstract][Full Text] [Related]
19. Analysis of fas ligand gene mutation in patients with systemic lupus erythematosus.
Kojima T; Horiuchi T; Nishizaka H; Sawabe T; Higuchi M; Harashima SI; Yoshizawa S; Tsukamoto H; Nagasawa K; Niho Y
Arthritis Rheum; 2000 Jan; 43(1):135-9. PubMed ID: 10643709
[TBL] [Abstract][Full Text] [Related]
20. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations.
Korkolopoulou P; Goudopoulou A; Voutsinas G; Thomas-Tsagli E; Kapralos P; Patsouris E; Saetta AA
Urology; 2004 Jun; 63(6):1198-204. PubMed ID: 15183989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
